New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
March 9, 2025 - Celltrion announced the FDA approval of Omlyclo (omalizumab-igec), biosimilar and interchangeable to Novartis/Genentech’s Xolair (omalizumab).
Download PDF
Return to publications
